**Summary and Rewrite:** Blockchain For Impact (BFI), a healthcare fund initiated during India’s COVID-19 pandemic, has partnered with the CSIR-Central Drug Research Institute (CDRI) to enhance biomedical research and foster healthcare innovation. This collaboration, part of the BFI-BIOME Virtual Network Program, targets pressing clinical needs in malaria, dengue, and metabolic diseases while setting the groundwork for future healthcare advancements in India. As a catalyst funder in the blockchain arena, BFI focuses on forming multi-sector partnerships to address India’s healthcare challenges and support marginalized communities. It has also teamed up with the Translational Health Science and Technology Institute (THSTI) to expedite research on vaccines, infectious diseases, diagnostics, and metabolic conditions, aligning with India’s Viksit Bharat (developed India) vision for 2047 and strengthening its biotechnological leadership. BFI's commitment extends to significant funding, with over $150, 000 allocated to healthcare startups at the Indian Institute of Technology Kanpur (IITK) and $900, 000 over three years to the Indian Institute of Technology Bombay for boosting biomedical research. Collaborations with the Indian Institute of Science (IISc) are also underway to support vital life sciences projects. Despite advancements in adopting technologies like blockchain and artificial intelligence (AI) for enhanced patient care and data security, managing patient data remains challenging. Blockchain can provide a secure, transparent platform to streamline data sharing between pharmaceutical companies and researchers, thus hastening the development of new treatments. A report by PwC indicates that healthcare organizations globally are benefiting from blockchain in health data management, accreditation, and supply chain processes.

Yet, the Indian healthcare sector will gradually adopt these technologies as they undergo research and validation. India’s new BioE3 (Biotechnology for Economy, Employment, and Environment) Policy is a pivotal step in advancing the biotechnology sector by promoting innovative research and biomanufacturing. This policy aims to develop infrastructure such as Bio-Artificial Intelligence hubs to drive research in bio-based products, essential for producing drugs, vaccines, and diagnostic tools. The BioE3 Policy outlines strategies to enhance biomanufacturing, leveraging India’s position as one of the top six bio-manufacturers globally. Minister Jitendra Singh highlighted the importance of technology in ensuring equitable healthcare access and improving efficiency in delivery systems. India’s biomanufacturing industry has seen explosive growth, projected to reach $130 billion by 2024, with the biotechnology sector potentially expanding to $300 billion by 2030. Singh emphasized India’s pivotal role in global vaccine production and the need for continued innovation and investment in biotechnology to cement its leadership position.